Compare TBPH & AXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBPH | AXG |
|---|---|---|
| Founded | 2013 | 2021 |
| Country | United States | Hong Kong |
| Employees | N/A | 33 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 712.4M |
| IPO Year | 2013 | N/A |
| Metric | TBPH | AXG |
|---|---|---|
| Price | $16.34 | $3.54 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $18.40 | N/A |
| AVG Volume (30 Days) | ★ 282.6K | 115.3K |
| Earning Date | 05-04-2026 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $8.46 | $28.53 |
| Revenue Next Year | N/A | $54.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.10 | $2.69 |
| 52 Week High | $21.03 | $4.75 |
| Indicator | TBPH | AXG |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 41.96 |
| Support Level | $16.14 | $3.49 |
| Resistance Level | $17.21 | $3.94 |
| Average True Range (ATR) | 0.38 | 0.11 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 29.31 | 10.34 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.